Sema4 Holdings Corp - Ordinary Shares - Class A Aktie News

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties to shareholders. If you currently own GeneDx stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved ...

GeneDx Holdings Corp. (WGS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

GeneDx Holdings Corp. is positioned as a leader in advanced exome and genome diagnostics, leveraging its expanding rare disease dataset. Fourth quarter preliminary results met guidance but did not exceed it sufficiently for a high multiple stock, resulting in a pullback. Company's 2026 guidance was strong and above expectations with testing volume growth of 33-35%.

GeneDx stock (NASDAQ: WGS) plunged 14% on Monday after the genomics testing company released preliminary full-year 2025 results that met expectations. But the company unveiled 2026 guidance that investors deemed disappointingly conservative, wiping out significant gains and reigniting concerns about the high-growth biotech's ability to maintain breakneck expansion.

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx reported high growth and profitability in preliminary results for the fourth quarter and full year of 2025 and issued 2026 guidance.

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Komodo Health Partner to Build the World's Most Complete Longitudinal Rare Disease Dataset.

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announced GenomeDx Prenatal™, a whole genome sequencing test that delivers fast, comprehensive insights when fetal anomalies are identified.

GAITHERSBURG, Md.--(BUSINESS WIRE)--Dr. Linda Genen named CMO to further strengthen GeneDx's commitment to delivering earlier answers and better outcomes through genomic insights.